Comparative effectiveness of infliximab and adalimumab for Crohn's disease.

[1]  M. V. van Oijen,et al.  Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: results from the COIN study , 2012, Gut.

[2]  S. Hanauer,et al.  Treat the Patient or Treat the Disease? , 2012, Digestive Diseases.

[3]  D. Hommes,et al.  Changing Crohn's disease management: need for new goals and indices to prevent disability and improve quality of life. , 2012, Journal of Crohn's & colitis.

[4]  J. Kremer,et al.  A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry , 2012, Annals of the rheumatic diseases.

[5]  Jeffrey R Curtis,et al.  Initiation of tumor necrosis factor-α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. , 2011, JAMA.

[6]  P. Rutgeerts,et al.  Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial , 2011, Gut.

[7]  J. Doshi,et al.  Measurement and rates of persistence with and adherence to biologics for rheumatoid arthritis: a systematic review. , 2011, Clinical therapeutics.

[8]  E. Keystone,et al.  Persistence with Anti-Tumor Necrosis Factor Therapies in Patients with Rheumatoid Arthritis: Observations from the RADIUS Registry , 2011, The Journal of Rheumatology.

[9]  A. Hart,et al.  Patient preference in choosing biological therapy in Crohn's disease. , 2011, Inflammatory bowel diseases.

[10]  J. Chao,et al.  Comparison of medical costs among patients using adalimumab and infliximab: a retrospective study (compairs) , 2010, Gut.

[11]  P. Rutgeerts,et al.  Infliximab, azathioprine, or combination therapy for Crohn's disease. , 2010, The New England journal of medicine.

[12]  I. Christensen,et al.  Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. , 2010, Arthritis and rheumatism.

[13]  P. Rutgeerts,et al.  Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. , 2009, Gastroenterology.

[14]  D. Baker.  Certolizumab pegol for the treatment of Crohn’s disease , 2009, Expert review of clinical immunology.

[15]  C. Gabay,et al.  Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis. , 2009, Arthritis and rheumatism.

[16]  P. Rutgeerts,et al.  Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. , 2008, Gastroenterology.

[17]  P. Callegari,et al.  Treatment persistence with adalimumab, etanercept, or infliximab in combination with methotrexate and the effects on health care costs in patients with rheumatoid arthritis. , 2008, Clinical therapeutics.

[18]  L. Peyrin-Biroulet,et al.  Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. , 2008, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[19]  S. Hanauer,et al.  Treatment of inflammatory bowel disease: a review of medical therapy. , 2008, World journal of gastroenterology.

[20]  S. Schreiber,et al.  Certolizumab pegol for the treatment of Crohn's disease. , 2007, The New England journal of medicine.

[21]  J. Lewis.  Anti-TNF antibodies for Crohn's disease--in pursuit of the perfect clinical trial. , 2007, The New England journal of medicine.

[22]  P. Rutgeerts,et al.  Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn’s disease , 2007, Gut.

[23]  A. Silman,et al.  Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. , 2007, Arthritis and rheumatism.

[24]  P. Rutgeerts,et al.  Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. , 2007, Gastroenterology.

[25]  M. Silverberg,et al.  Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[26]  U. Gasthuisberg.  Infliximab for induction and maintenance therapy for ulcerative colitis , 2006 .

[27]  Paul Rutgeerts,et al.  Infliximab for induction and maintenance therapy for ulcerative colitis. , 2005, The New England journal of medicine.

[28]  P. Austin,et al.  Reader's guide to critical appraisal of cohort studies: 2. Assessing potential for confounding , 2005, BMJ : British Medical Journal.

[29]  M. Bala,et al.  Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. , 2005, Gastroenterology.

[30]  R. Rau,et al.  Treatment continuation in patients receiving biological agents or conventional DMARD therapy , 2005, Annals of the rheumatic diseases.

[31]  Douglas G Altman,et al.  Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses , 2003, BMJ : British Medical Journal.

[32]  An Carbonez,et al.  Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. , 2003, The New England journal of medicine.

[33]  E. Keystone,et al.  The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. , 2002, Arthritis and rheumatism.

[34]  S. Hanauer,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[35]  M. Sandra Wood,et al.  Health care financing administration , 2000 .

[36]  M. Bala,et al.  Annual cost of care for Crohn's disease: a payor perspective , 2000, American Journal of Gastroenterology.

[37]  R. Deyo,et al.  Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. , 1992, Journal of clinical epidemiology.